1 | areteam board of directors | | | | | | | 2 | 1.19% |
2 | visualization to reduce unintended | | | | | | | 2 | 1.19% |
3 | nerve visualization to reduce | | | | | | | 2 | 1.19% |
4 | directors management team scientific | | | | | | | 2 | 1.19% |
5 | of directors management team | | | | | | | 2 | 1.19% |
6 | board of directors management | | | | | | | 2 | 1.19% |
7 | collaborations science about illuminare1 | | | | | | | 2 | 1.19% |
8 | canvas logo canvas logo | | | | | | | 1 | 0.60% |
9 | is in final stages | | | | | | | 1 | 0.60% |
10 | in final stages of | | | | | | | 1 | 0.60% |
11 | final stages of completing | | | | | | | 1 | 0.60% |
12 | stages of completing a | | | | | | | 1 | 0.60% |
13 | trial in radical prostatectomy | | | | | | | 1 | 0.60% |
14 | firstinhuman trial in radical | | | | | | | 1 | 0.60% |
15 | in radical prostatectomy at | | | | | | | 1 | 0.60% |
16 | radical prostatectomy at memorial | | | | | | | 1 | 0.60% |
17 | prostatectomy at memorial sloan | | | | | | | 1 | 0.60% |
18 | kettering cancer center to | | | | | | | 1 | 0.60% |
19 | cancer center to demonstrate | | | | | | | 1 | 0.60% |
20 | center to demonstrate safety | | | | | | | 1 | 0.60% |
21 | to demonstrate safety and | | | | | | | 1 | 0.60% |
22 | illuminare1 is in final | | | | | | | 1 | 0.60% |
23 | nerve illumination illuminare1 is | | | | | | | 1 | 0.60% |
24 | illumination illuminare1 is in | | | | | | | 1 | 0.60% |
25 | molecule with an immediate | | | | | | | 1 | 0.60% |
26 | our proprietary lead candidate | | | | | | | 1 | 0.60% |
27 | proprietary lead candidate illuminare1 | | | | | | | 1 | 0.60% |
28 | lead candidate illuminare1 is | | | | | | | 1 | 0.60% |
29 | candidate illuminare1 is a | | | | | | | 1 | 0.60% |
30 | illuminare1 is a small | | | | | | | 1 | 0.60% |
31 | logo canvas logo home | | | | | | | 1 | 0.60% |
32 | with an immediate onset | | | | | | | 1 | 0.60% |
33 | safety and initial efficacy | | | | | | | 1 | 0.60% |
34 | an immediate onset of | | | | | | | 1 | 0.60% |
35 | immediate onset of action | | | | | | | 1 | 0.60% |
36 | onset of action and | | | | | | | 1 | 0.60% |
37 | of action and sustained | | | | | | | 1 | 0.60% |
38 | action and sustained duration | | | | | | | 1 | 0.60% |
39 | and sustained duration of | | | | | | | 1 | 0.60% |
40 | demonstrate safety and initial | | | | | | | 1 | 0.60% |